PUBLICATIONS


hook-publications   *denotes corresponding author.

Selected Publications

  1. Xu J, Acharya S, Sahin Ö, Wang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery F, Kuo W, Xiao Y, Ensor J, Sahin A, Zhang X, Hung M, Zhang JD, Yu D (2015). 14-3-3ζ turns TGF-β’s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell.  doi:10.1016/j.ccell.2014.11.025.
  1. Uhlmann S, Mannsperger H, Zhang JD, Horvath EA, Schmidt S, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, Sahin Ö* (2012). Global microRNA level regulation of EGFR-driven cell cycle protein network in breast cancer. Mol Syst Biol. 8:570. (Featured article). doi: 10.1038/msb.2011.100.
  1. Sahin Ö, Wang Q, Brady S, Ellis K, Wang H, Li P, Chang C, Zhang Q, Priya P, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D (2014). Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research. 24(5):542-59. doi: 10.1038/cr.2014.37.
  1. Sahin Ö, Löbke C, Korf U, Appelhans H, Sültmann H, Poustka A, Wiemann S, Arlt D (2007) Combinatorial RNAi for quantitative protein network analysis. PNAS. 104:6579-6584. (Higlighted in the Issue). doi: 10.1073/pnas.0606827104.
  2. Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin Ö* (2013). Re-expression of microRNA375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 32(9):1173-82  doi: 10.1038/onc.2012.128.

 

Publication Bibliography

  1. Mutlu M, Saatci Ö, Ansari SA, Yurdusev E, Shehwana H, Konu Ö, Raza U, Şahin Ö* (2016). miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer. Scientific Reports. doi:10.1038/srep32541
  2. Raza U, Saatci Ö, Uhlmann S, Ansari SA, Eyüpoğlu E, Yurdusev E, Mutlu M, Ersan PE, Altundağ MK, Zhang JD, Doğan HD, Güler G, Şahin Ö* (2016). The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget. doi: 10.18632/oncotarget.10489
  3. Chia-Chi Chang, Chenyu Zhang, Qingling Zhang, Sahin Ö, Hai Wang, Jia Xu, Yi Xiao, Jian Zhang, Sumaiyah K. Rehman, Ping Li, Mien-Chie Hung, Fariba Behbod, Dihua Yu (2016). Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. doi: 10.18632/oncotarget.9136.
  4. Mutlu M, Raza U, Saatci Ö, Eyüpoğlu E, Yurdusev E, Sahin Ö* (2016). miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. Journal of Molecular Medicine. doi: 10.1007/s00109-016-1420-5.
  5. Xu J, Acharya S, Sahin Ö, Wang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery F, Kuo W, Xiao Y, Ensor J, Sahin A, Zhang X, Hung M, Zhang JD, Yu D (2015). 14-3-3ζ turns TGF-β’s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Celldoi:10.1016/j.ccell.2014.11.025.
  6. Haller F, Zhang JD, Moskalev EA, Braun A, Otto C, Geddert H, Riazalhosseini Y, Ward O, Balwierz A, Schaefer IM, Cameron S, Ghadimi BM, Agaimy A, Fletcher JA, Hoheisel J, Hartmann A, Werner M, Wiemann S, Sahin Ö (2015). Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors (GISTs) reveals hypomethylation of SPP1as an independent prognostic factor. International Journal of Cancer. doi: 10.1002/ijc.29088.
  7. Ward O, Shukla K, Balwierz A, Soons Z, König R, Sahin Ö, Wiemann S (2014). microRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumor-suppressor genes in ER+ breast cancer. The Journal of Pathology. doi: 10.1002/path.4363.
  8. Sahin Ö, Wang Q, Brady S, Ellis K, Wang H, Chang C, Zhang Q, Priya P, Zhu R, Wong S, Landis M, Muller W, Esteva F, Chang J, Yu D (2014). Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Researchdoi: 10.1038/cr.2014.37.
  9. Raza U, Zhang JD, Sahin Ö*  (2014). MicroRNAs: master regulators of drug resistance, stemness, and metastasis. Journal of Molecular Medicine. doi:10.1007/s00109-014-1129-2.
  10. Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin Ö*(2013). Re-expression of microRNA375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. doi: 10.1038/onc.2012.128.
  11. Shahmoradgoli M, Riazalhosseini Y, Haag D, Hovestadt V, Becker N, Mannherz O, Sinn HP, Schneeweiss A, Sahin Ö, Lichter P. (2013) Protein phosphatase 1, regulatory subunit 15B, PPP1R15B, is a survival factor rendering resistance in ERα-positive breast cancer. Int. J Cancer. doi: 10.1002/ijc.27945.
  12. Horvat EA, Zhang JD, Uhlmann S, SahinÖ, Zweig KA. (2013) A network-based method to assess the statistical significance of mild co-regulation effects. Plos ONE. 8(9): e73413. doi:10.1371/journal.pone.0073413.
  13. Rehman SK, Li SH, Wyszomierski SL, Wang Q, SahinÖ, Xiao Y, Li P, Zhang S, Xiong Y, Yang J, Guo H, Wang H, Medina D, Muller WJ, Yu D. (2013) 14-3-3zeta orchestrates mammary tumor onset and progression via miR221-mediated cell proliferation. Cancer Research. Nov 6. doi: 10.1158/0008-5472.CAN-13-2016. [Epub ahead of print].
  14. Issa A, Gill JW, SahinÖ, Wiemann S, Dey J and Hynes NE (2013). Combinations of FGF and ErbB receptor inhibitors in breast cancer models block Erk and PI3K signaling, tumor growth and metastatic spread. Breast Cancer Res. 15(1):R8. doi: 10.1186/bcr3379.
  15. Botla SK, Gholami AM, Malekpour M, Moskalev EA, Fallah M, Jandaghi P, Aghajani A, Bondar IS, Omranipour R, Malekpour F, Mohajeri A, Babadi AJ, Sahin Ö, Bubnov VV, Najmabadi H, Hoheisel JD, Riazalhosseini Y.(2013) Diagnostic values of GHSR DNA methylation pattern in breast cancer. Breast Can Res and Treat. 135(3):705-13. doi: 10.1007/s10549-012-2197-z.
  16. Uhlmann S, Mannsperger H, Zhang JD, Horvath EA, Schmidt S, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, Sahin Ö* (2012). Global microRNA level regulation of EGFR-driven cell cycle protein network in breast cancer. Mol Syst Biol. 8:570. (Featured article) Comment in News&Views by Malumbres (2012), Mol Syst Biol, 8:569doi: 10.1038/msb.2011.100.
  17. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S*, Sahin Ö* (2012). MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol. 32(3):633-51. doi: 10.1128/MCB.06212-11.
  18. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, Sahin Ö, Wiemann S, Tschulena U (2012). MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene. 31(37):4150-63. doi: 10.1038/onc.2011.571.
  19. Wang Q, Li S, Wang H, Xiao Y, Sahin Ö, Brady SW, Li P, Xiong Y,  Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D (2012). Concomitant targeting of tumor cells and induction of T cell response synergizes to inhibit trastuzumab-resistant breast cancer. Cancer Research. 72(17):4417-28.  doi: 10.1158/0008-5472.CAN-12-1339-T
  20. Zhang JD, Koerner C, Bechtel S, Bender C, Keklikoglou I, Schmidt C, Irsigler A, Ernst U, Sahin Ö, Wiemann S, Tschulena U (2011). Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. PLoS ONE. 6(7):e22176. doi: 10.1371/journal.pone.0022176.
  21. Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, RiazalhosseiniY, Burmester S, Ward A, Korf U, Wiemann S, Sahin Ö* (2010). miR-200bc/429 cluster targets PLCγ1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene. 29(30):4297-306. doi: 10.1038/onc.2010.201.
  22. HallerF, von HeydebreckA, ZhangJD, Gunawan B, LangerC, RamadoriG, Wiemann S, Sahin Ö (2010). Localisation- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs) with a cluster of coexpressed miRNAs located at 14q32.31. Journal of Pathology. 220(1):71-86. doi: 10.1002/path.2610.
  23. Mannsperger HA, Uhlmann S, Schmidt C, Wiemann S, Sahin Ö and Korf U (2010). RNAi-based validation of antibodies for reverse phase protein arrays. Proteome Science. 8(1):69. doi:10.1186/1477-5956-8-69.
  24. Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, Diederichs S, Sahin Ö, Mayer D, Lyko F, Hoheisel JD, Riazalhosseini Y (2010). Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with Estrogen Receptor α in breast cancer cells. Cancer Research. 70(22):9175-84. doi: 10.1158/0008-5472.CAN-10-1318.
  25. Sahin Ö*, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, Mattern J, Schupp I, Chaouiya C, Thieffry D, Poustka A, Wiemann S, Beissbarth T, Arlt D* (2009). Modeling  ERBB receptor regulated G1/S transition network in de novo trastuzumab resistant breast cancer. BMC Systems Biology. 3:1. doi:10.1186/1752-0509-3-1. (Indicated as highly accessed on BioMed Central).
  26. Fröhlich H , Sahin Ö, Arlt D, Bender C, Beissbarth T (2009). Deterministic effects propagation networks for reconstructing protein signaling networks from multiple interventions. BMC Bioinformatics. 10:322. doi:10.1186/1471-2105-10-322.
  27. Sahin Ö and Wiemann S (2009) Functional genomics and proteomics approaches to study the ERBB-network in cancer. (Review). FEBS Lett  583(11):1766-71. doi: 10.1016/j.febslet.2009.03.031. (invited)
  28. Korf U, Löbke C, Sahin Ö, Haller F, Sültmann H, Arlt D, Poustka A (2009) Reverse phase protein arrays (RPPA) for application-orientated cancer research (Review). Proteomics – Clinical Applications. 3(10): 1140–1150. DOI: 10.1002/prca.200780035
  29. Sauermann M, Sahin Ö, Sültmann H, Hahne F, BlaszkiewiczS, Majety M, Zatloukal K, Füzesi L, Poustka A, Wiemann S, Arlt D (2008) Reduced expression of Vacuole membrane protein 1 (Vmp1) affects the invasion capacity of tumor cells. Oncogene. 27(9):1320-6. doi:10.1038/sj.onc.1210743.
  30. Löbke C, Laible M, Rappl C, Ruschaupt M, Sahin Ö, Arlt D, Wiemann S, Poustka A, Sültmann H, Korf U (2008) Contact-spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signalling. Proteomics. 8(8):1586-94. doi: 10.1002/pmic.200700733.
  31. Sahin Ö, Löbke C, Korf U, Appelhans H, Sültmann H, Poustka A, Wiemann S, Arlt  D (2007) Combinatorial RNAi for quantitative protein network analysis. PNAS. 104:6579-6584. doi: 10.1073/pnas.0606827104(Higlighted in the Issue).
  32. Arlt D, Sahin Ö, Korf U, Loebke C, Beißbarth T, Hahne F, Wiemann S, Poustka A (2006) Modeling breast cell cycle regulation – overcoming drug resistance. Conf Proc IEEE Eng Med Biol Soc.1:40-3. DOI: 10.1109/IEMBS.2006.259761.

Other Publications

Book Chapters:

Mannsperger H, UhlmannS, Korf U, Sahin Ö* (2010). Utilization of RNAi to validate antibodies for reverse phase protein arrays. Methods in Molecular Biology (Springer NY/Humana Press) 785: 4(45-54). doi: 10.1007/978-1-61779-286-1_4.

Online publications:

Mutlu M, Saatçi Ö, Raza U, Eyüpoglu E, Yurdusev E, Sahin Ö* (2014). MIR200C (microRNA 200c). Atlas Genet Cytogenet Oncol Haematol. July 2014.

Jurmeister S, Uhlmann S, Sahin Ö* (2011). MIR200C (microRNA 200c). Atlas Genet Cytogenet Oncol Haematol. August 2011.

In German:

Haller F, Zhang DJ, Löbke C, von Heydebreck A, Korf U, Füzesi L, Sahin Ö (2010). Multilayer analysis of signal transduction and cell cycle control in GIST: Identifying new interaction partners with differential regulation. Pathologe 31 Suppl 2:134-7 (in German). doi: 10.1007/s00292-010-1339-5.